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A B S T R A C T
Here, we validate the use of a novel fluorescent norepinephrine transporter (NET) substrate for dynamic mea-
surements of transporter function in rodent cardiovascular tissue; this technique avoids the use of radiotracers
and provides single-terminal resolution.
Rodent (Wistar rats and C57BL/6 mice) hearts and mesenteric arteries (MA) were isolated, loaded with NET
substrate Neurotransmitter Transporter Uptake Assay (NTUA) ex vivo and imaged with confocal microscopy.
NTUA labelled noradrenergic nerve terminals in all four chambers of the heart and on the surface of MA. In all
tissues, a temperature-dependent, stable linear increase in intra-terminal fluorescence upon NTUA exposure was
observed; this was abolished by NET inhibitor desipramine (1 μM) and reversed by indirectly-acting sym-
pathomimetic amine tyramine (10 μM). NET reuptake rates were similar across the mouse cardiac chambers. In
both species, cardiac NET activity was significantly greater than in MA (by 62 ± 29% (mouse) and 21 ± 16%
(rat)). We also show that mouse NET reuptake rate was twice as fast as that in the rat (for example, in the heart,
by 94 ± 30%). Finally, NET reuptake rate in the mouse heart was attenuated with muscarinic agonist carbachol
(10 μM) thus demonstrating the potential for parasympathetic regulation of norepinephrine clearance.
Our data provide the first demonstration of monitoring intra-terminal NET function in rodent cardiovascular
tissue. This straightforward method allows dynamic measurements of transporter rate in response to varying
physiological conditions and drug treatments; this offers the potential to study new mechanisms of sympathetic
dysfunction associated with cardiovascular disease.
1. Introduction
Noradrenergic volume transmission depends on the interplay be-
tween norepinephrine (NE) release and its subsequent reuptake by the
norepinephrine transporter (NET). The presynaptically located NET
terminates the action of NE through a Na+/Cl−-dependent secondary
active transport process, which transports NE back into nerve terminals
(Iversen, 1963; Esler et al., 1990), and hence represents an important
determinant of NE availability in the extracellular space. However,
inferences of dynamic changes in NET reuptake rate in mature sym-
pathetic nerve terminals are difficult to achieve, relying on indirect
measurements such as NE overflow (with and without NET inhibition)
(Esler et al., 1988; Grassi and Esler, 1999) or tissue reuptake of
radioactive substrates on a macroscopic scale (Pandit-Taskar and
Modak, 2017; Chen et al., 2019).
Tools to directly study NET kinetics in mature sympathetic nerve
terminals are needed in order to better understand transporter regula-
tion, which has been shown to be impaired in several cardiovascular
diseases (Schroeder and Jordan, 2011, 2012), and is frequently used as
a target for pharmacotherapeutics (Zhou, 2004). Fluorescence imaging
has proved useful in discerning individual synapses microscopically at
high temporal resolutions and, indeed, our group demonstrated the use
of a fluorescent NET substrate to measure NET function in sympathetic
terminals of the mouse vas deferens (Parker et al., 2010). An additional
benefit of this technique is the ability to identify such terminals
amongst a mix of peripheral neuronal types; for example, in addition to
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noradrenergic innervation, the heart possesses a combination of choli-
nergic and nitrergic efferent terminals and sensory nerves (Shivkumar
and Ardell, 2016) that are all varicose and morphologically similar
(Mitchell, 1953). Being able to simultaneously label for noradrenergic-
specific nerves and measure NET transporter function would prove
valuable for the understanding of reuptake properties of the NE term-
inals ex vivo and in vivo. Of particular interest is how NET reuptake
rate may change in response to varying pathophysiological conditions,
for example in disease states and pharmacological manipulations.
Here, we expand the use of a fluorescent NET substrate to the car-
diovascular system, more specifically in the rodent heart and mesen-
teric arteries, to further understand NET kinetics and its regulation.
Using this approach, we studied intra- and interspecies differences in
intra-terminal NET transporter kinetics, NET protein temperature de-
pendency as well as beginning an exploration of the effects of auto-
nomic interplay on NE clearance in the heart.
2. Material and methods
2.1. Ethical approval
All animal care and experimental protocols of this present in-
vestigation were undertaken in accord with the ethical guidelines set
out by the Animals (Scientific Procedures) Act 1986, National Institutes
of Health and the University of Birmingham, United Kingdom.
Procedures were performed under UK Home Office license (mouse: PPL
PFDAAF77F, rat: PPL PF4C074AD). Animals were housed in in-
dividually ventilated cages under standard conditions: 12:12 h light/
dark cycle (with light beginning at 0700), 22 °C and 55% humidity.
Food and water were available ad libitum.
2.2. Animals and tissue isolation
Male and female C57BL/6 mice and male Wistar rats were supplied
by Charles River Laboratories (Margate, UK). Animals were rendered
unconscious using deep general anaesthesia (3–5% isoflurane in O2,
flow rate 1.5 L·min−1). Mouse hearts were subsequently rapidly iso-
lated, while rat hearts and rodent first or second order mesenteric ar-
tery/vein bundles were isolated following an approved humane Home
Office schedule 1 method: cervical dislocation, confirmation by ex-
sanguination. Tissues were maintained in bicarbonate buffered Krebs-
Henseleit solution (KH) containing (mM): NaCl 118, NaHCO3 25,
KH2PO4 1.2, glucose 11, EDTA 0.5, MgSO4 1.2, CaCl2 2.5, KCl 4.7 and
equilibrated with 95% O2/5% CO2, pH 7.4.
2.3. Measurement of norepinephrine transporter rate
To dynamically measure norepinephrine transporter (NET) rate, we
utilised the commercially available Neurotransmitter Transporter
Uptake Assay (NTUA, R8173; https://www.moleculardevices.com/
products/assay-kits/transporters/neurotransmitter-transporter-
uptake#gref, San Jose, CA; U.S. Patent # 6420183, 7063952, 7138280
and European Patent # 0906572) kit. NTUA contains a fluorescent
substrate for biogenic amine transporters, including NET, and a
masking dye that extinguishes extracellular fluorescence.
Rodent cardiac chambers (LAA, left atrial appendage; RAA, right
atrial appendage; LV, left ventricle; RV, right ventricle) and mesenteric
arteries (MA) were dissected free as described (Holmes et al., 2016;
Hansen et al., 2019), transferred to the imaging chamber and securely
pinned down as flat as possible onto a Sylgard-lined base. Tissues were
continuously superfused at 2 ml·min−1 with warmed (35–37 °C), oxy-
genated KH solution for at least 20 min prior to ex vivo studies. The
imaging chamber was positioned underneath an upright confocal
scanning microscope (Olympus Fluoview FV1000).
The NTUA protocol used throughout was adapted from previous
work by our laboratory (Parker et al., 2010). Due to the lack of nerve
terminal autofluorescence, tissues were initially superfused with a
highly-diluted (1:100) NTUA solution for 10 and 20 min for mouse and
rat, respectively, in order to visualise the location of nerve terminals.
After this time, three control z-stacks of areas of high innervation
density consisting of ~15 slices at 1 μm intervals were imaged. In
studies to explore the effects of some drugs, there was a 6 min pre-
treatment period. Tissues were then exposed to a less-dilute solution of
NTUA (1:20) and z-stacks of the same area were imaged every 1 or
2 min. In some experiments, the preparation was returned to KH
thereafter in the presence and absence of pharmacological intervention
to investigate fluorescence washout in five minute intervals. To de-
monstrate the overall innervation in this field for visual purposes, z-
stacks were merged. The imaging software (Olympus FV10-ASW 4.2)
was configured to take 512 × 512 pixel images on a one-way mode at
2.0 μs/pixel with wavelength filter set: excitation 405 nm (circa 1%
laser power)/emission 460–560 nm with the pinhole as narrow as
possible to exclude out-of-focus light.
2.4. Image analysis
Image analysis was performed with Fiji (version 1.52a; https://fiji.
sc). To quantify the increase in terminal-specific raw fluorescence ex-
erted by NTUA, a region of interest (ROI) was selected around a single
nerve terminal at its brightest amongst the first control z-stack. The
mean fluorescence value was extracted and the same ROI was manually
restored in subsequent stacks. To obtain terminal-specific emission in-
tensities, background fluorescence values surrounding the ROI were
subtracted from this value.
To measure changes in NET reuptake rate independent of the initial
raw fluorescence across experiments (as determined by native uptake of
NTUA, confocal detection sensitivity and pinhole diameter), values
(1:20, F1:20, t) at each time point, t, were normalised to the average of its
three control values (1:100, F1:100) with the equation shown below and
the NET reuptake rate was determined by the trendline gradient vari-








Similarly, to investigate the decline in fluorescence during washout,
the trendline gradient variable was quantified from the fitted linear
decline in fluorescence signal.
2.5. Fluorescence histochemistry
To visualise intra-terminal catecholamines, rodent hearts and MA
were subjected to a sucrose-potassium-glyoxylic acid (SPG) solution (De
la Torre, 1980). Hearts were isolated, embedded in cryoprotectant on a
cork disc with the cardiac chamber of interest facing up and then
quickly frozen in isopentane cooled in liquid nitrogen. Several 10 μm
thick cryosections were obtained, transferred to slides and immediately
dipped in room temperature SPG solution for 3 s (1 dip/s). Often in the
same animal, mesenteric arteries were isolated and immediately sub-
merged in SPG solution for 40 min and stretched out on slides. Tissue
slides (heart and vessels) were dried entirely under a cool stream of air
facilitated by a desk fan until ground-glass appearance, mounted with
mineral oil and heated to 75 °C for 30 min before sealed with a cov-
erslip. The sections were captured with a confocal microscope fitted
with an oil objective (Olympus FV1000; 40× 1.3 NA) with wavelength
filter set: excitation 405 nm/emission 460–560 nm.
2.6. Drugs
NTUA was provided in vials containing its powder form. A total of
10 ml of buffered KH was added to each vial to yield 1:1 NTUA, then
split into 50 × 200 μL aliquots and frozen (−20 °C). Desipramine,
tyramine, carbachol and atropine (all drugs, Sigma) were made up to
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10 mM aliquots with water and also frozen. On the day of use, these
aliquots were further diluted with buffered KH to yield the final
working concentrations.
2.7. Data analysis
Values are expressed as mean ± SEM. Normality of data was
checked with a Kolmogorov-Smirnov test. Statistical analysis of nor-
malised data was carried out by unpaired Student's t-test, or Welch's
correction t-test if the variance in data differed; Mann-Whitney test was
used as a non-parametric equivalent. Friedman one-way ANOVA test
followed by Dunn's multiple comparison test was carried out on data
consisting of more than two groups. When reporting percentage dif-
ferences between datasets, errors of the respective data were combined
as the root of the sum of squares of relative errors.
All statistical analyses were carried out on GraphPad Prism (version
8; GraphPad Software Inc., San Diego, CA, USA). p < 0.05 was con-
sidered statistically significant. Several n abbreviations are used in the
text: (i) n is the number of animals and (ii) nt is the number of in-
dividual terminals. Statistical analysis was performed on ‘nt’ numbers.
3. Results
3.1. NTUA labelling and histofluorescence staining
Superfusion of rodent cardiac chamber and mesenteric arteries with
the NTUA kit revealed networks of sympathetic innervation where
coursing axonal bundles can be seen branching out into thinner bundles
and ultimately, to thin varicose fibres (left panels – heart: Fig. 1 (rat),
Fig. 2 (mouse); left and middle panels – mesenteric artery: Fig. 3). The
latter structures are characterised by their classical appearance of
‘beads on a string’ morphology demonstrating the terminal part of the
axon. We also loaded NTUA into mouse hearts via Langendorff perfu-
sion (method analogous to Yu et al. (2014), O'Shea et al. (2019)), which
resulted in labelling of similar structures (n = 2, data not shown). It is
interesting to note some non-neuronal fluorescence seen in the NTUA-
treated rodent heart (Figs. 1, 2). Note that under control conditions
(prior to adding 1:100 NTUA), no structures resembling nerve terminals
were observed.
To demonstrate noradrenergic nerves with an alternative method,
we incubated a different set of rodent tissue in a SPG solution. In the
heart, this revealed an occasional supply of individual nerve fibres with
punctate structures similar to those observed with NTUA. However,
axonal bundles were not seen with this method (right panels; heart:
Fig. 1 (rat), Fig. 2 (mouse)). Similarly to NTUA labelling, SPG-treated
mesenteric arteries resulted in the appearance of very dense plexuses of
noradrenergic bundles that innervates the entirety of the vessel. How-
ever, while nerve bundles consisting of multiple nerve fibres were
evident in NTUA-treated arteries, this was not seen in SPG-treated ar-
teries. In addition to this, nerve structures in the latter treatment ap-
peared ‘scrunched’ compared to their counterparts.
3.2. NTUA specificity for NET
To confirm that NTUA uptake into the structures of interest de-
pended on NET, rodent tissues were pre-treated with the NET inhibitor
desipramine (1 μM, DSM) for 6 min prior to and during the test period
with 1:20 NTUA. This abolished NTUA uptake into nerve terminals
during the linear phase in the LAA (rat: control: 7.2 ± 0.9%·min−1 vs.
DSM: −1.4 ± 0.02%·min−1; p < 0.0001 (Fig. 4A, B); mouse: control:
28.4 ± 4.1%·min−1 vs. DSM: −2.5 ± 0.5%·min−1; p < 0.0001
(Fig. 4C, D)) and MA (rat: control: 3.7 ± 0.3%·min−1 vs. DSM
−1.2 ± 0.3%·min−1; p < 0.0001 (Fig. 5A, B); mouse: control:
18.3 ± 4.8%·min−1 vs. DSM: −0.3 ± 0.8%·min−1; p < 0.0001
(Fig. 5C, D)). In addition to this, specificity was also investigated with
NET reverse substrate tyramine (TYR, 10 μM); following the 1:20 NTUA
test period, mouse LAA preparations were returned to KH with or
without TYR. In the presence of TYR, the fall in NTUA fluorescence
during washout over the first 5 min was 54 ± 5% greater than with KH
alone (control: −12.1 ± 1.7%·min−1 vs. TYR: −26.4 ± 2.5%·min−1;
p < 0.0001, Fig. 6B). Thereafter, the tyramine group slope tended
towards −1.0 au as individual nerve terminals could no longer be seen
while identification remained possible in the control group (Fig. 6A).
3.3. Intraspecies and interspecies differences in NET mediated NTUA
uptake
To investigate intra- and interspecies variation in the NET reuptake
rate of singular noradrenergic nerve terminals of rodent cardiovascular
tissue, the rates of NTUA uptake in adult animals were compared be-







Fig. 1. NTUA and SPG labelling of noradrenergic nerves in the rat heart. NTUA
labelling (left panels) and glyoxylic acid-induced histofluorescence (SPG; right
panels) of each chamber of the rat heart, i.e. left atrial appendage (LAA), right
atrial appendage (RAA), left ventricle (LV) and right ventricle (RV). NTUA la-
belled noradrenergic axonal bundles can be seen dividing off into single fibre
axons with punctate swellings of nerve terminals (yellow arrows). The latter
was also seen by SPG histofluorescence (white arrows). Yellow arrow heads
mark the presence of non-neuronal fluorescence in response to NTUA treat-
ment.
For all micrographs, bars = 10 μm.
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each species, the NTUA reuptake rate was consistently faster in the
heart than the MA: 62 ± 29% higher in the rat (LAA
6.5 ± 0.6%·min−1 vs. MA 4.0 ± 0.3%·min−1; p < 0.01, Fig. 7A) and
21 ± 16% higher in the mouse (LAA 12.7 ± 0.8%·min−1 vs. MA
10.5 ± 1.1%·min−1; p < 0.01, Fig. 7B). We also compared NET re-
uptake rates across the cardiac chambers in the mouse heart; there were
no differences across the atria and ventricles on both the left side and
right side (LAA: 12.7 ± 0.8%·min−1, RAA: 13.2 ± 1.0%·min−1, LV:
11.4 ± 0.7%·min−1, RV: 14.7 ± 1.4%·min−1; p > 0.05, Fig. 7C).
This suggests a homogenous NET reuptake rate confined to single nerve
terminals in the heart, though this is consistently faster than those in
the mesenteric arteries.
Between species, the NTUA uptake rate was significantly faster by a
two-fold difference in the mouse than the rat in both the LAA (Fig. 8A)
and the MA (Fig. 8B) by 94 ± 30% and 160 ± 77%, respectively,
suggesting for clear species differences in NET reuptake rate.
3.4. Temperature-dependent kinetics
To determine if the uptake of NTUA into noradrenergic nerve
terminals depended on the rate of carrier-mediated transport rather
than passive diffusion, the effect of temperature was investigated in
mouse LAA. When the organ bath temperature was cooled by 10 °C for
6 min prior to and during 1:20 NTUA superfusion, the trace of NTUA
uptake was shallower (Fig. 9A) the rate of uptake was reduced by
nearly three-fold (from control values of 20.0 ± 2.4%·min−1 to
6.5 ± 0.7%·min−1; p < 0.0001; Fig. 9B).
3.5. Muscarinic regulation of NET
To investigate cholinergic influences on NET reuptake rate in the
heart, we exposed the mouse LAA to carbachol (10 μM) during the
6 min pre-treatment time and during the 1:20 NTUA test period. This
resulted in a reduction in NET-dependent NTUA reuptake rate by
70 ± 36% (control: 20.0 ± 2.4%·min−1 vs. carbachol:
11.8 ± 0.7%·min−1; p < 0.001; Fig. 10). By pre-treating the tissue
with the muscarinic antagonist atropine (1 μM), the NET reuptake rate
was recovered to values similar to control (15.1 ± 1.2%·min−1;
p > 0.05), indicating functional presynaptic muscarinic receptors on
noradrenergic nerve terminals.
3.6. Susceptibility to photobleaching
As the investigation of intrinsic NET reuptake rate depended on
frequent imaging protocols, we were interested in the photostability of
the NTUA fluorescence in the mouse LAA. Under constant imaging
conditions every 2 min for 20 min, NTUA fluorescence steadily atte-
nuated over time. However, in reduced imaging conditions consisting of
absent illumination for 10 min, fluorescence was maintained at sig-
nificantly higher values at the protocol endpoint (Fig. 11A); we quan-
tified this as the change in fluorescence between t = 6 and t = 20
(constant: −0.47 ± 0.07 vs. reduced: 0.25 ± 0.09, p < 0.0001;
Fig. 11B).
4. Discussion
4.1. The use of fluorescence to monitor transporter activity
Literature reports of norepinephrine transporter (NET) kinetics for
the past three decades have relied heavily on the use of radiotracers in
cells (Raffel et al., 2013), animals (Lopez-Picon et al., 2019; Chen et al.,
2019) and humans (Wichter et al., 2002; Pandit-Taskar and Modak,
2017). Unfortunately, in addition to the disadvantages associated with
nuclear safety, expenses and requirement for specialist personnel, the
data obtained on real-time changes in NET regulation and function are
limited and confined to the macroscopic scale. However, during this
time, fluorescence imaging diversified and the use of common dyes in
the field of NETs was developed, including stilbazolium dyes, for ex-
ample 4-[4-(dimethyl amino)styryl]-N-methylpyridinium iodide
(ASP+; analogue of neurotoxin, MPP+) (Haunso and Buchanan, 2007;
Wilson et al., 2012) and false fluorescent neurotransmitters (Dunn
et al., 2018), which both provide the ability to discern individual
terminals microscopically in living tissue.
In this present study, we adapted the use of a novel and commer-
cially available fluorescent kit, Neurotransmitter Transporter Uptake
Assay (NTUA), to monitor NET reuptake rate in rodent heart and blood
vessels at the spatiotemporal resolution of single noradrenergic nerve
terminals. So far, this technique has been validated in cell culture
systems (Jorgensen et al., 2008), including cardiac stellate sympathetic
neurones (Shanks et al., 2013), as well as the intact mouse vas deferens
(Parker et al., 2010). We demonstrate, for the first time, the use of this
method in rodent cardiovascular tissue ex vivo and its applicability to







Fig. 2. NTUA and SPG labelling of noradrenergic nerves in the mouse heart.
NTUA labelling (left panels) and glyoxylic acid-induced histofluorescence (SPG;
right panels) of each chamber of the mouse heart, i.e. left atrial appendage
(LAA), right atrial appendage (RAA), left ventricle (LV) and right ventricle
(RV). NTUA labelling and SPG histofluorescence yielded visualisation of nora-
drenegic neurones with single fibre axons. Yellow arrow heads mark the pre-
sence of non-neuronal fluorescence in response to NTUA treatment.
For all micrographs, bars = 10 μm.
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manipulations, such as temperature- and drug-induced effects.
4.2. NTUA as a labelling method for sympathetic nerve terminals in
cardiovascular tissue
The nerve terminal branches seen upon exposure to NTUA super-
fusion are structurally similar to sympathetic nerve terminals described
elsewhere (Rysevaite et al., 2011; Yokomizo et al., 2015) and as seen
with glyoxylic acid labelling (as we show here). These punctate struc-
tures are joined by intervaricose segments and are indicative of synapse
formation (Bennett, 1993; Brain et al., 1997); tracing them backwards,
they combine with others to form small bundles of fibres, which ulti-
mately form large nerve bundles. In the heart, the latter structures and
single nerve fibres have been found in the epicardium and close to
cardiomyocytes (Kawano et al., 2003), respectively. However, this
exact distribution was difficult to determine as it was challenging to
flatly secure the tissue in the superfusion bath. Additionally, NTUA
labelling could only be seen to a depth of a few tens of micrometers,
which is likely to have been limited by the depth penetration of the
microscope under the current recording conditions (Pawley, 2006). We
also cannot rule out a failure of the dye to penetrate deep into the tissue
from the epicardial surface. To overcome this, we have also achieved
labelling of nerve terminals using Langendorff perfusion; while this is
helpful for studies that require the mere identification of sympathetic
innervation, it is less suitable for the study of kinetics due to difficulty
of imaging while perfusing. Interestingly, in the heart, NTUA super-
fusion led to increases in fluorescence of non-neuronal structures, si-
milar to that described in the mouse vas deferens (Parker et al., 2010).
However, this was not problematic for nerve terminal identification as
its morphology was distinct and fluorescence was significantly brighter
than non-neuronal fluorescence.
Significant advantages of NTUA labelling over histochemical
staining are that it does not require tissue cryosection, which could
have prevented the visualisation of axonal bundles in this study, and it
can be used as an intravital stain. NTUA labelling does not suffer from
the disadvantage of shrinkage artefacts induced by dehydration that
occurs with fixation methods, including glyoxylic acid labelling. Such
shrinkage may explain why the glyoxylic acid-treated terminals of ro-
dent mesenteric arteries appear compressed. This also led to difficulties
in identifying individual nerve fibres that constitute nerve bundles,
unlike those labelled with NTUA (compare image panels in Fig. 3).
Shrinkage artefacts prevent accurate nerve density quantification even
with stretched preparations (Furness and Costa, 1975) and it is difficult
to count individual fibres in bundles. Therefore, in addition to the ad-
vantages of NTUA for ex vivo studies, it also maintains physiological
nerve architecture and structure.
4.3. Mechanisms of NTUA uptake
Transport by NET (and other monoamine transporters) is driven by
a Na+/Cl−-secondary active process (Apparsundaram, 2001) and up-
take has been shown to be temperature-dependent with ASP+
(Schwartz et al., 2003; Mason et al., 2005) and 3H-NE (Inazu et al.,
2003). Here, we show a three-fold reduction in NTUA uptake rate in
cooler temperatures (25–27 °C) compared to physiological tempera-
tures. This is similar to the Q10 (ratio between transport activity at two
temperatures differing by 10 °C) value of 2.5 previously reported for
ASP+ transport by hNET (Mason et al., 2005), thus strongly suggesting
carrier-mediated (rather than passive) uptake in this study.
The NTUA assay is also a substrate for the dopamine- and serotonin
transporter (DAT and SERT, respectively). Whilst DAT expression and
function has been detected in the guinea pig heart (Palomar et al.,
2011) and in the rabbit celiac artery (Amenta and Ferrante, 1983),
respectively, there is currently no evidence of its existence in rodent
cardiovascular tissue (Mitsuma et al., 1998). In addition to this, desi-
pramine is a more potent inhibitor of NET (Ki = 7.36 nM) than DAT
(Ki > 10,000 nM) (Zhou, 2004), thus the complete abolition of NTUA
uptake in this study suggests against the role of DAT in NTUA uptake.
SERT, on the other hand, has been consistently observed in rodent
cardiovascular structures, for example valves (Gustafsson et al., 2005;
Pavone et al., 2008) and endocardium (Mekontso-Dessap et al., 2006),
and arterial smooth muscle (Ni et al., 2004). However, SERT in these
NTUA (low magnification) SPGNTUA (high magnification)
RAT
MOUSE
Fig. 3. NTUA and SPG labelling of noradrenergic nerves in the rodent mesenteric arteries. At high magnifications, NTUA incubation (left panels; yellow arrows)
labelled noradrenergic nerves at the level of single terminals. At low magnifications, NTUA (middle panels) and SPG (right panels) incubation demonstrated
perivascular noradrenergic nerves arranged in thick bundles that wraps around the entirety of the vessel.
For all micrographs, bars = 10 μm.
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studies were shown to be present in valve interstitial cells, the inner-
most layer of cardiac chamber lining and nerve independent, respec-
tively. As we focused on the uptake of NTUA into neuronal structures
present in the subepicardium and on the surface of perivascular nerves,
the contribution of SERT to NTUA uptake was also unlikely. Therefore,
NET is most likely uptake mechanism of NTUA in rodent heart and
mesenteric artery.
To further support for NET specificity, we next hypothesised faster
loss of intra-terminal NTUA fluorescence during washout in the pre-
sence of a NET reverse substrate. Here, tyramine, a NET substrate that
stimulates peripheral release by reverse transport through NET (Pei
et al., 2016), led to an over two-fold uniform decline in NTUA fluor-
escence during the washout phase compared to the control group.
Tyramine releases monoamines from vesicular stores (Trendelenburg
et al., 1987); it appears that the rapid loss of NTUA fluorescence in this
study was mediated by a release of NTUA into the cytoplasm followed
by extrusion by the reversal of the NET transporter. This was also
previously demonstrated in the mouse vas deferens where storage was
reversed by amphetamine, another indirectly-acting sympathomimetic
amine (Parker et al., 2010). The use of a VMAT and NET transporter
substrate to deplete NTUA fluorescence further supports the idea that
NTUA is stored in sympathetic terminals and their vesicles.
4.4. Intraspecies differences in NET reuptake rate
Having demonstrated NTUA uptake is NET-specific, we determined
if NET reuptake rate differed between organs and within different parts
of the heart. We show that, in both the rat and mouse, nerve terminals












































































































Fig. 4. NTUA uptake into noradrenergic nerves is NET-specific in rodent left atrial appendages (LAA).
NTUA accumulation into noradrenergic terminals during the 1:20 NTUA test period was completely abolished by tissue pre-treatment with desipramine (DSM, 1 μM).
The linear traces in which the NET reuptake rate in the heart was obtained are shown in A (rat) and C (mouse). The gradient variables were extracted and quantified
in B (rat) and D (mouse).
Rat LAA, control (n = 4, nt = 25) vs. DSM (n = 4, nt = 23).
Mouse LAA, control (n = 4, nt = 24) vs. DSM (n = 4, nt = 24).
Data presented as mean ± SEM. **** denotes p < 0.0001. Welch's t-test.
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present in the heart exhibit faster NET reuptake rate than those in the
mesenteric arteries, suggesting that norepinephrine (NE) reuptake rate
differs between these tissues. A similar difference was reported pre-
viously in the somas of isolated rat postganglionic neurones from the
cardiac stellate ganglia compared to those from the superior mesenteric
ganglia (Shanks et al., 2013). Additionally, on a macroscopic scale, the
heart has been shown to exhibit a greater dependence on NET for NE
removal compared to other organs in mice (Krell and Patil, 1972), rats
(Thackeray et al., 2007), monkeys (Farde et al., 1994) and humans
(Goldstein et al., 1988). This functional asymmetry is important as it
implies differences in cellular signalling and in autonomic regulation
between tissues. Indeed, one study found selective impairment of NET
in cardiac stellate postganglionic neurones in SHRs compared to WKYs
(Shanks et al., 2013). However, whether this is due to a higher NET
expression density, NET variants or faster transport kinetics of in-
dividual NET in these tissues is currently unknown and to our knowl-
edge, there are no studies that directly compare this.
In the mouse heart, there appeared to be similar terminal-specific
NET reuptake rates across each cardiac chamber. A previous study also
demonstrated homogeneous reuptake of radiolabelled NE in the
grouped mouse atria and ventricles (Shirey-Rice et al., 2013), thus
suggesting for cardiac symmetry in NET reuptake rate. However, there
are also separate reports of highest NET reuptake rate found in the left
ventricle (Wehrwein et al., 2008) and right ventricle (Raffel et al.,
2006). Those studies, however, quantify total tissue NET reuptake rate
rather than terminal-specific reuptake, as we have shown here; the
latter may collectively sum up to macroscopic differences, though this
requires further study. Most importantly, tissue reuptake also depends
on the density of terminals and tissue volume. To our knowledge, there
are currently no other studies that have studied intraspecies differences
in terminal-specific NET reuptake rate across the heart.
Heterogeneous NET reuptake rates in the left ventricle have been
reported in various species (Chilian et al., 1982; Munch et al., 2005;
Kusmic et al., 2019), including rodents (Kiyono et al., 2002; Ieda et al.,
2007), although in humans it appears as homogeneous except in disease
states (Beau and Saffitz, 1994; Kiyono et al., 2001; Wichter et al.,
2002). This is thought to contribute to electrical heterogeneity and thus
arrhythmogenesis found in heart failure (Beau and Saffitz, 1994) and
Brugada syndrome patients (Wichter et al., 2002). In this study, we
made no attempt to quantify NET reuptake rate throughout the left
ventricle. However, we present a tool for others to investigate cardiac
heterogeneity further for distinct populations of sympathetic nerve
terminals throughout the heart. This would prove clinically relevant as
sympathetic defects are linked to sudden death in these patients and
offers an opportunity to address important mechanistic questions.
4.5. Interspecies differences in NET reuptake rate
In this study, we also show a two-fold faster NET reuptake rate in
the mouse than rat in both heart and vascular tissue. To our knowledge,










































































































Fig. 5. NTUA reuptake into noradrenergic nerves is
NET-specific in rodent mesenteric arteries (MA).
NTUA accumulation into noradrenergic terminals
during the 1:20 NTUA test period was completely
abolished by tissue pre-treatment with desipramine
(DSM, 1 μM). The linear traces in which the NET
reuptake rate in the heart was obtained are shown in
A (rat) and C (mouse). The gradient variables were
extracted and quantified in B (rat) and D (mouse).
Rat MA, control (n = 4, nt = 24) vs. DSM (nt = 24).
Unpaired t-test.
Mouse MA, control (n = 4, nt = 24) vs. DSM
(nt = 24). Mann-Whitney U test.
Data presented as mean ± SEM. **** denotes
p < 0.0001.
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research into interspecies differences in transporter function have so far
been studied very rarely. Currently, only one group has investigated
such differences and, similar to our study, also found a two-fold faster
reuptake rate in perfused isolated whole hearts in the mouse than rat
(Iversen et al., 1971). While another group have also investigated NE
reuptake in hearts of rats (Krell and Patil, 1972) and mice (Garg et al.,
1973), these took place as separate studies and differed in their tech-
nical and analytical methods, thus their respective results cannot be
directly compared. One explanation for interspecies differences is the
dissimilarity of NET transporter kinetics. While rat NET have been
shown to have 90% amino acid identity to its mouse counterparts
(Ensembl database (Zerbino et al., 2017)), there are no studies that
directly compare their functional kinetic differences; however, this has
been shown to be present between rat-, bovine- and human-NET
(Paczkowski et al., 1999). To better understand the results of this pre-
sent study, future work could investigate individual transporter
function (substrate molecules per protein per second) across species, as
described elsewhere (Schwartz et al., 2003). Nevertheless, this current
study is the first to compare interspecies differences in terminal-specific
NET reuptake rate between the two most commonly used species in
biomedical research.
4.6. Muscarinic inhibition of NET rate in the heart
Sympathetic postganglionic neurones are endowed with hetero-
receptors that modulate neurotransmitter release (Schlicker and
Göthert, 1998). In the present study, we explored the effects of one
possible heteroreceptor on NE clearance mechanisms. We found a
muscarinic (carbachol)-mediated reduction in NET reuptake rate, si-
milar to that described previously in the mouse vas deferens (Parker
et al., 2010). Studies with isolated guinea pig chromaffin cells have also
shown reduced NE reuptake with acetylcholine (Role and Perlman,
1983). In SK-N-SH cells, this effect has been shown to be governed by a
protein kinase C (PKC)-dependent mechanism (likely M3 receptor sub-
type) (Apparsundaram et al., 1998a), which also parallels findings with
PKC activator β-PMA (Apparsundaram et al., 1998b). The muscarinic-
NET effect may be facilitated by NET/syntaxin 1A interactions as the
PKC-mediated disruption caused by muscarinic agonists in CHO-M3
cells led to an increased propensity for NET redistribution and a parallel
decrease in intrinsic activity (Sung et al., 2003). Whether or not this
effect in the present study was mediated by M1 or M3 receptors (two
subtypes coupled to Gq in whole heart tissue (Saternos et al., 2018)) is
currently unknown.
Muscarinic inhibition of norepinephrine release has been well-in-
vestigated in the cardiovascular system (Fozard and Muscholl, 1972;
Manabe et al., 1991) and it has been interpreted as a source of cross-
inhibition from parasympathetic to sympathetic terminals (Ritter et al.,
2020). Here, we demonstrate a muscarinic inhibition of NET reuptake
rate, the functional effect of which would be to amplify noradrenergic
neurotransmission. A simple interpretation of this is that the inhibition
of NET reuptake partially negates or even reverses the cross-inhibition
of release. The relative importance of such a mechanism in the presence
of exocytosis and reuptake inhibition may depend on factors such as the
spatiotemporal release of both acetylcholine and norepinephrine at
once in the heart. For example, during periods of strong sympathetic
and parasympathetic co-activation (“autonomic conflict”) such as cold-
water submersion (Paton et al., 2005), there is evidence to demonstrate
its tendency for arrhythmogenesis (Winter et al., 2018), thus we spec-
ulate that such co-activation coupled with attenuated NET function
might lead to an overall pathological augmentation of noradrenergic-
driven electrical instability to the heart.
Despite these explanations however, we cannot rule out the possi-
bility of an alternative mechanism of action: carbachol acting post-
junctionally to release mediators for retrograde signalling to the nerve
terminals. Such retrograde signalling following muscarinic receptor
activation has been shown to be important in the brain (Thomsen et al.,
2018), but its role in the periphery, including the heart, has not yet
been explored. Therefore, although the direct action of carbachol on the
nerve terminals here seems speculative, at present it is the most par-
simonious explanation for the current results.
4.7. Photosensitivity of NTUA
To demonstrate the photosensitivity of NTUA, we investigated the
effect of constant illumination vs. reduced illumination protocols. We
found that with reduced illumination, the attenuation of fluorescence
signal following the initial linear rise in the minute-by-minute protocol
was diminished, thus highlighting the experimental limitation asso-
ciated with fluorescence imaging. This questions the present study de-
sign and whether monitoring NET reuptake of NTUA at each minute,
rather than just the start- and end-point, was necessary. However, as
this study focused on the use of a fluorescent substrate to dynamically
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Fig. 6. NET substrate tyramine induced rapid loss of intra-terminal fluores-
cence in mouse LAA.
Mouse LAA were subjected to 1:20 NTUA test period for 6 min and promptly
returned to KH with or without tyramine (10 μM) and imaged in 5 min inter-
vals. After 5 min, the loss of fluorescence in the TYR group was significantly
faster than in the control group. Within 10 min of TYR exposure, fluorescence of
some nerve terminals was completely lost as the slope tended towards −1,
while they remained visible in the control group (A). The gradient variables
were extracted for the first 5 min and quantified in B.
Control (n = 4, nt = 24) vs. TYR (n = 4, nt = 24).
Data presented as mean ± SEM. **** denotes p < 0.0001. Unpaired t-test.
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monitor transporter kinetics, frequent illumination protocols were es-
sential. Despite this, there is scope for future studies to identify key time
points and image as necessary to prolong the overall duration of ima-
ging and minimise perturbations to physiological processes.
Researchers should also take care of accurate protocol reporting and
adherence to imaging parameters for experimental replication.
5. Future directions
We have optimised a new optical technique to dynamically monitor




























































































Fig. 7. Tissue differences in NTUA uptake rate within each species.
NET reuptake rate was faster in the LAA compared to MA in the rat (A) and mouse (B); LAA (n = 4, nt = 24) vs. MA (n = 4, nt = 24). Mann-Whitney U test. This did
not differ across the mouse heart (C); all four chambers: n = 4, nt = 24, Friedman test followed by Dunn's multiple comparison test.
Data presented as mean ± SEM. ** denotes p < 0.001, Ns denotes p > 0.05.




























































A B Fig. 8. Species differences (rat vs. mouse)
in NTUA uptake rate in left atrial appen-
dage (LAA) and mesenteric arteries (MA).
In the mouse, NET reuptake rate was faster
in both the LAA (A) and MA (B) by ap-
proximately two-fold; rat (n = 4, nt = 24)
vs. mouse (n = 4, nt = 24).
Data presented as mean ± SEM. **** de-
notes p < 0.0001. Mann-Whitney U test.
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NET reuptake rate in the heart and blood vessel ex vivo. This should
prove valuable for studies of sympathetic nerve function under various
phenotypes, e.g. hypertensive rats, and/or various conditions, for ex-
ample different pharmacological agents; ultimately, allowing the me-
chanisms underlying these conditions to be elucidated. Previous work
with SHRs found impairment of NET reuptake rate in the soma of iso-
lated cardiac postganglionic neurones (Shanks et al., 2013) compared
to WKY controls; with this present technique it would be interesting to
see if this is consistent at neuroeffector sites at the level of the tissue.
Moreover, extending this technique to an in vivo setting would be of
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A B Fig. 9. NTUA uptake into noradrenergic nerve
terminals is temperature-dependent in the mouse left
atrial appendage.
The trace of NTUA uptake into terminals was shal-
lower in cooler temperatures during the 1:20 NTUA
test period compared to physiological temperatures
(A). The gradient variables were extracted and
quantified in B. The rate of NTUA uptake was re-
duced by three-fold when the bath temperature was
lowered by 10 °C prior to and during the test period
(B) 35–37 °C (n = 4, nt = 24) vs. 25–27 °C (n = 4,
nt = 24).
Data presented as mean ± SEM. **** denotes
p < 0.0001. Mann-Whitney U test.


























































Fig. 10. Effect of muscarinic agonist car-
bachol on NET reuptake rate into nora-
drenergic terminals of the mouse left atrial
appendage.
Pre-treatment with muscarinic receptor
agonist carbachol (10 μM) reduced NET
reuptake rate of NTUA. This was prevented
by the inclusion of muscarinic receptor an-
tagonist atropine (1 μM). Control (n = 4,
nt = 24) vs. carbachol (n = 4, nt = 24) vs.
atropine (n = 4, nt = 24). The gradient
variables were extracted and quantified in
B.
Data presented as mean ± SEM. *** de-
notes p < 0.001, ns denotes p > 0.05;
Kruskal-Wallis test followed by Dunn's
multiple comparison test (B).



















































A B Fig. 11. Frequent imaging protocols re-
sulted in an attenuation of NTUA-induced
fluorescence intensity in nerve terminals of
the mouse left atrial appendage.
(A) Timeline of NTUA-induced fluorescence
in different imaging conditions. Constant
imaging conditions (2-minute intervals for
20 min) resulted in an attenuation of nor-
malised fluorescence intensity between
t = 6 and t = 20 (n = 4, nt = 19); the
opposite was true when an absence of
imaging occurred at t = 8–18 (n = 4,
nt = 24).
(B) The change of normalised fluorescence
intensity between t = 6 and t = 20 in
different imaging conditions. The constant
imaging conditions tended towards a ne-
gative change in normalised fluorescence
intensity whereas there a positive change
for the reduced imaging conditions.
Constant (n = 4, nt = 19) vs. reduced
(n = 4, nt = 24), unpaired Student's t-test.
Data presented as mean ± SEM. **** de-
notes p < 0.0001.
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interest to allow for investigations of central and local paracrine effects
on NET transporter regulation.
6. Conclusion
To conclude, the overall significance of this present study is the
validation of a new fluorescent tool to measure intra-terminal NET
function at the site of action in cardiovascular tissue ex vivo. With this
method, we found symmetrical NET reuptake rates throughout the
mouse heart, which were significantly faster than vascular tissue; NET
reuptake kinetics were also consistently faster in mouse than rat, i.e. the
two most used species in biomedical research. We also began to explore
muscarinic drug action on NET to investigate possible influences of
parasympathetic regulation on NE clearance. We hope this new tech-
nique will help unveil important mechanisms that regulate NET in
varying physiological conditions, drug treatments and disease states.
Finally, we predict that it will be a valuable tool in order to reveal new
mechanisms of sympathetic dysfunction associated with cardiovascular
disease.
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